Current treatments are estimated to only reduce about one-third of the disease burden of depressive disorders. Prevention may be an alternative strategy to further reduce the disease burden of ...

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when ...

Patients with non-seasonal depression who were treated with bright light therapy reported a 40% remission rate, according to a recent study.

Bipolar disorder is a long-term mood disorder characterized by major fluctuations in mood — both high and low — that can ...

But this year, the U.S. Food and Drug Administration cleared the first app-based treatment for major depressive disorder ... The idea is to tap into the brain’s circuits so depressive signals and ...

A device that delivers direct brain stimulation has been shown to be a safe and effective home-based treatment for major depressive disorder (MDD) in a new study published in Nature Medicine. The ...

de Filippis, R. and Al Foysal, A. (2024) Case Report: The Role of Monoamine Oxidase Inhibitors in Treating Resistant Depression. Open Access Library Journal, 11, 1-12. doi: 10.4236/oalib.1112369 .

The primary endpoint was the change from baseline to the end of the 6-week double-blind treatment period on the MADRS, which is the standard regulatory endpoint in depression. The study was ...

its Phase 3 pivotal program evaluating the efficacy and safety of CYB003 for the adjunctive treatment of Major Depressive Disorder (“MDD”). The program name, PARADIGM, represents the Company's ...

In an earlier Phase 2 study of SP-624, Arrivo explored efficacy over placebo during a 4-week treatment period ... an initial episode of depression can evolve into a recurrent and debilitating ...